Acumen Pharmaceuticals (ABOS) Scheduled to Post Earnings on Tuesday

Acumen Pharmaceuticals (NASDAQ:ABOS) is set to issue its quarterly earnings data before the market opens on Tuesday, May 14th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter.

Acumen Pharmaceuticals (NASDAQ:ABOS) last posted its quarterly earnings results on Tuesday, March 26th. The company reported ($0.29) EPS for the quarter, meeting the consensus estimate of ($0.29). On average, analysts expect Acumen Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Acumen Pharmaceuticals Stock Up 1.5 %

Shares of ABOS traded up $0.05 during mid-day trading on Wednesday, hitting $3.41. The company’s stock had a trading volume of 21,155 shares, compared to its average volume of 354,413. The company has a current ratio of 19.01, a quick ratio of 19.01 and a debt-to-equity ratio of 0.11. The company’s 50-day moving average is $3.84 and its 200-day moving average is $3.33. Acumen Pharmaceuticals has a 52-week low of $1.81 and a 52-week high of $11.31. The firm has a market capitalization of $204.87 million, a price-to-earnings ratio of -3.23 and a beta of 0.19.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Acumen Pharmaceuticals in a report on Wednesday, March 27th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $12.25.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers.